trans-diethyl 1-benzylpyrrolidine-3,4-dicarboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: trans-diethyl 1-benzylpyrrolidine-3,4-dicarboxylate
• 英文别名: Diethyl 1-benzylpyrrolidine-3,4-dicarboxylate
• 化学式: C₁₇H₂₃NO₄
• 分子量: 305.374
• InChiKey: QXELSODIWMVNCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  trans-diethyl 1-benzylpyrrolidine-3,4-dicarboxylate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.3h， 以93.9%的产率得到(1-苄基吡咯烷-3,4-二基)二甲醇
  参考文献：
  名称：

  CATIONIC LIPID

  摘要：

  本发明提供了一种阳离子脂质，其允许核酸轻松进入细胞，其表示为式(I)（其中：R1和R2为相同或不同的烯基等，X1和X2为氢原子，或结合在一起形成单键或烷基，X3不存在或为烷基等，Y不存在或为阴离子，a和b为相同或不同的0到3，L3为单键等，R3为烷基等，L1和L2为—O—，—CO—O—或—O—CO—），一种包含该阳离子脂质和核酸的组合物，以及一种通过使用包含该阳离子脂质和核酸的组合物将核酸引入细胞的方法，等等。

  公开号：

  US20130280305A1

文献信息

• [EN] NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE PYRROLIDINE-3,4-DICARBOXAMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005092881A1

  公开（公告）日：2005-10-06

  The invention is concerned with novel pyrrolidine-3,4-dicarboxamide derivatives of Formula (I) ; wherein Rl to R9 and X are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.

  这项发明涉及一种新型的 Formula (I) 中的吡咯烷-3,4-二羧酰胺衍生物；其中 R1 到 R9 和 X 如描述和索赔中定义的那样，以及其生理上可接受的盐。这些化合物抑制凝血因子 Xa，可用作药物。
• Quinolizinone type compounds
  申请人：Abbott Laboratories

  公开号：US05599816A1

  公开（公告）日：1997-02-04

  Antibacterial compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, selected preferred examples of which include those compounds wherein A is.dbd.CR.sup.6 --; R.sup.1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R.sup.2 is selected from the group consisting of ##STR2## R.sup.3 is halogen; R.sup.4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R.sup.5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR.sup.13 R.sup.14 ; and R.sup.6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.

  具有以下公式的抗菌化合物##STR1##以及其药学上可接受的盐，酯和酰胺，其中选定的首选示例包括其中A是.dbd.CR.sup.6--; R.sup.1是三到八个碳原子的环烷基或取代苯基; R.sup.2选自##STR2## R.sup.3是卤素; R.sup.4是氢，低碳基，药学上可接受的阳离子或前药酯基; R.sup.5是氢，低碳基，卤代（低碳基），或--NR.sup.13 R.sup.14; R.sup.6是卤素，低碳基，卤代（低碳基），羟基取代的低碳基，低碳氧（低碳基），低碳氧或氨基（低碳基），以及包含此类化合物的制药组合物以及其在治疗细菌感染方面的用途。
• Organic Compounds
  申请人：Ehrhardt Claus

  公开号：US20080194549A1

  公开（公告）日：2008-08-14

  The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.

  本发明涉及使用(3,4-二-, 3,3,4-三-, 3,4,4-三-或3,3,4,4-四-)取代吡咯烷化合物制备治疗依赖于肾素活性的疾病的药物制剂；使用该类化合物治疗依赖于肾素活性的疾病；该取代吡咯烷化合物亚类的化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病；该取代吡咯烷化合物亚类的新化合物；包括所述取代吡咯烷化合物的药物制剂和/或包括给予所述取代吡咯烷化合物的治疗方法，特别是制备该新取代吡咯烷化合物的方法，以及其合成的新中间体、起始材料和/或部分步骤。
• Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof
  申请人：FUCHINO Kouki

  公开号：US20100216726A1

  公开（公告）日：2010-08-26

  The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.

  本发明涉及取代喹喔啉型哌啶化合物、包含有效量取代喹喔啉型哌啶化合物的组合物以及治疗或预防某种疾病（如疼痛）的方法，包括向需要治疗的动物施用有效量取代喹喔啉型哌啶化合物。
• PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN
  申请人：Breitenstein Werner

  公开号：US20100087427A1

  公开（公告）日：2010-04-08

  Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula I wherein the substituents are as described in the specification.

  小说3-单一、3,4-二和3,4,4-三取代吡咯烷化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖于肾素不适当活性的疾病（=失调）；该类化合物用于制备用于治疗依赖于肾素不适当活性的疾病的制药配方；该类化合物用于治疗依赖于肾素不适当活性的疾病；包括所述取代吡咯烷化合物的制药配方和/或包括给予所述取代吡咯烷化合物的治疗方法，以及描述了制备所述取代吡咯烷化合物的新型中间体和部分步骤。所述取代吡咯烷化合物特别是公式I的取代基如说明书所述。